Global Pneumococcal Vaccination Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pneumococcal Vaccination Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
Pneumococcal Vaccination report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pneumococcal Vaccination market is projected to reach US$ 16100 million in 2029, increasing from US$ 7841.5 million in 2022, with the CAGR of 10.6% during the period of 2024 to 2029. Demand from Child and Adult are the major drivers for the industry.
The pneumococcal vaccination market is driven by the increasing awareness of the importance of vaccination and the rising incidence of pneumococcal infections. Pneumococcal vaccines are crucial in preventing diseases caused by Streptococcus pneumoniae bacteria, such as pneumonia, meningitis, and bacteremia. The rise in the geriatric population and the need for immunization against respiratory infections contribute to market growth as pneumococcal vaccines offer significant benefits in reducing morbidity and mortality. Moreover, advancements in vaccine technology, such as the introduction of conjugate vaccines for broader protection, have improved vaccine efficacy. However, the market also faces challenges, including vaccine supply constraints and the need for continuous research to address emerging pneumococcal serotypes and strains. Additionally, addressing vaccine hesitancy and increasing vaccination coverage in underserved populations can pose obstacles for comprehensive disease prevention. To succeed, companies must focus on research and development to offer innovative and affordable pneumococcal vaccines, collaborate with healthcare providers to promote vaccination recommendations, and address the challenges to meet the increasing demand for effective and accessible protection against pneumococcal infections.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pneumococcal Vaccination market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer
GSK
MSD
CDIBP
WALVAX
Sinovac
Bio Kangtai
Segment by Type
PPSV 23
PCV 13
PCV 10
Child
Adult
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Pneumococcal Vaccination market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pneumococcal Vaccination, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pneumococcal Vaccination industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Pneumococcal Vaccination in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pneumococcal Vaccination introduction, etc. Pneumococcal Vaccination Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Pneumococcal Vaccination market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Pneumococcal Vaccination report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pneumococcal Vaccination market is projected to reach US$ 16100 million in 2029, increasing from US$ 7841.5 million in 2022, with the CAGR of 10.6% during the period of 2024 to 2029. Demand from Child and Adult are the major drivers for the industry.
The pneumococcal vaccination market is driven by the increasing awareness of the importance of vaccination and the rising incidence of pneumococcal infections. Pneumococcal vaccines are crucial in preventing diseases caused by Streptococcus pneumoniae bacteria, such as pneumonia, meningitis, and bacteremia. The rise in the geriatric population and the need for immunization against respiratory infections contribute to market growth as pneumococcal vaccines offer significant benefits in reducing morbidity and mortality. Moreover, advancements in vaccine technology, such as the introduction of conjugate vaccines for broader protection, have improved vaccine efficacy. However, the market also faces challenges, including vaccine supply constraints and the need for continuous research to address emerging pneumococcal serotypes and strains. Additionally, addressing vaccine hesitancy and increasing vaccination coverage in underserved populations can pose obstacles for comprehensive disease prevention. To succeed, companies must focus on research and development to offer innovative and affordable pneumococcal vaccines, collaborate with healthcare providers to promote vaccination recommendations, and address the challenges to meet the increasing demand for effective and accessible protection against pneumococcal infections.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pneumococcal Vaccination market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer
GSK
MSD
CDIBP
WALVAX
Sinovac
Bio Kangtai
Segment by Type
PPSV 23
PCV 13
PCV 10
Segment by Application
Child
Adult
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Pneumococcal Vaccination market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pneumococcal Vaccination, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pneumococcal Vaccination industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Pneumococcal Vaccination in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pneumococcal Vaccination introduction, etc. Pneumococcal Vaccination Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Pneumococcal Vaccination market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices